Search

Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the first-in-human results using 177Lu-FAP-2286 for peptide-targeted radionuclide therapy (PTRT). Methods: PTRT using 177Lu-FAP-2286 was performed in 11 patients with advanced adenocarcinomas of pancreas, breast, rectum and ovary after prior confirmation of uptake on 68Ga-FAP-2286/-FAPI-04- PET/CT. Results: Administration of 177Lu-FAP-2286 (5.8 ± 2.0 GBq; range, 2.4–9.9 GBq) was well tolerated, with no adverse symptoms or clinically detectable pharmacologic effects being noticed or reported in any of the patients. The whole-body effective doses were 0.07 ± 0.02 Gy/GBq (range 0.04 – 0.1). The mean absorbed doses for kidneys and red marrow were 1.0 ± 0.6 Gy/GBq (range 0.4 – 2.0) and 0.05 ± 0.02 Gy/GBq (range 0.03 – 0.09), respectively. Significant uptake and long tumor retention of 177Lu-FAP-2286 resulted in high absorbed tumor doses, e.g., 3.0 ± 2.7 Gy/GBq (range 0.5 – 10.6) in bone metastases. No grade (G) 4 adverse events were observed. G3 events occurred in 3 patients – 1 pancytopenia, 1 leukocytopenia and 1 pain flare-up; 3 patients reported pain-response. Conclusion:177Lu-FAP-2286 PTRT, applied in a broad spectrum of cancers, was relatively well-tolerated with acceptable side effects and demonstrated long retention of the radiopeptide. Prospective clinical studies are warranted.

Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the first-in-humans results using

Introduction: According to the new National calendar of immunization of 2012, specific vaccination against tuberculosis (TB) in the Republic of Belarus is held to all newborns on the 3-5th day of life, as well as to children at the age of 7 from the risk-group of TB. Aim: To assess the dynamics of clinical and epidemiological indicators of TB over a ten year period after the reform of child TB service. Objectives: Carry out an analysis of case-histories of children admited in the Centre of Pulmonology and Tuberculosis in 2002-2003 and 2012-2014. To analyze and compare the structure of clinical forms of TB. Methods: A comparative analysis of major clinical and epidemiological indicators of TB in children infected in 2002-2003 and 2012-2014. Results: Socio-hygienic characteristics of children with TB for the ten-year period in the country has not changed. Clinical characteristics of TB improved: the number of destructive forms decreased from 36.3 to 21.3%, as well as complicated and common forms of TB in the risk-group of children (from 51.9% to 15.2%). However, there is an increasing tendency towards infiltrative forms (from 30 to 48%) and multidrug resistant TB (from 4.8 to 17.2% among children from healthy environment, and from 22.6 to 29.8% in the risk-group of children). Conclusions: The reforms of child TB service did not lead to a declension of clinical and epidemiological indicators and allowed to save money.